Heat Biologics, Inc. (HTBX)
| Market Cap | 155.43M |
| Revenue (ttm) | 2.45M |
| Net Income (ttm) | -29.38M |
| Shares Out | 25.14M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,721 |
| Open | 6.20 |
| Previous Close | 6.27 |
| Day's Range | 6.10 - 6.29 |
| 52-Week Range | 5.22 - 17.00 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 20.67 (+237.7%) |
| Est. Earnings Date | Nov 9, 2021 |
About HTBX
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with a...
Financial Performance
In 2020, Heat Biologics's revenue was $2.95 million, a decrease of -3.32% compared to the previous year's $3.05 million. Losses were -$26.05 million, 30.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 20.67, which is an increase of 237.75% from the latest price.
News
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune sys...
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune sys...
Heat Biologics to Provide Corporate Update
Conference call scheduled for September 2nd at 11:00 AM ET Conference call scheduled for September 2nd at 11:00 AM ET
Heat Biologics Is Starting To Run Away From Support Toward Resistance
Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday morning after the company announced the launch of its wholly-owned subsidiary Skunkworx Bio Inc. focused on developing a drug discovery pa...
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Developing a new era of precision medicines using a unique and proprietary drug discovery platform Developing a new era of precision medicines using a unique and proprietary drug discovery platform
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the im...
Heat Biologics Provides Second Quarter 2021 Business Update
DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the im...
Heat Biologics Announces Groundbreaking for New San Antonio Facility
Groundbreaking ceremony to be streamed live Groundbreaking ceremony to be streamed live
Heat Biologics Joins Russell Microcap® Index
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syst...
Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
Investments expected to accelerate development timelines and reduce development expenses Investments expected to accelerate development timelines and reduce development expenses
Heat Biologics Surges On Patent Filing
Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday after the company filed for a patent titled “GP96-Based Cancer Therapy.” The stock was trending on StockTwits throughout the day and is li...
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patient...
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients Survival benefit observed in two treatment settings of previously treated non-small lung cancer p...
Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study
Heat Biologics Inc (NASDAQ: HTBX) has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in ...
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Pre...
DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syste...
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syste...
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune syst...
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vacci...
DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the imm...
NSPR Stock: What You Should Know About InspireMD Today
InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity an...
DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...
Heat Biologics Provides Year-End Business Update
DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...
Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, inc...
HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today
Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska. The post HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today ap...
Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival
Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.
Heat Biologics News: Why HTBX Stock Is Going Gangbusters Today
Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangbusters Tod...
Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally
Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (niv...